Dr Gopal Pemmaraju gives insights on the causes, risk factors, types, symptoms and treatment for head and neck cancer. Learn more about the warning signals ... Dec 17
HPV is transmitted sexually. Nearly all sexually active people once in their lifetime get infected with HPV. It can affect both men and women and ... Dec 08
Esophageal speech is the backup option. In this method, the speech-language therapist teaches the patient how to swallow before teaching them how to burp ... Jul 13
Cervical cancer is often referred to as a "silent killer" because it often presents no symptoms in its early stages. Warning signs may appear as ... Jun 17
Latest Pharma News Update... Aug 31
... Jul 22
... Jul 17
Immutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021. ... Jul 12
Surgery is currently the most common treatment option for the treatment of NMSC which often carry significant cutaneous adverse events, risk of scar, infection, bleeding ... Apr 27
This worldwide exclusive license to Merck KGaA, Darmstadt, Germany for the development and commercialization of Xevinapant ... Mar 03
The primary endpoint of this trial was to evaluate patients for complete histological clearance of the tumour cells within the treated isSCC lesion... Dec 21
OncoBeta, announced today that the Rhenium-SCT (Rhenium-188 paste) has been registered on the Australian Register of Therapeutic Goods (ARTG), which is the formal ... Dec 19
... Dec 18
Bristol Myers Squibb announced the approval of Opdivo for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma ... Nov 25
QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck ... Nov 19
LENVIMA plus everolimus were evaluated versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma... Nov 10
This acquisition is well positioned to achieve its maximum potential to benefit appropriate cancer patients in need... Nov 06
Libtayo is indicated for advanced non-smal cell cancer with PD-L1 Expression of ≥50%... Oct 31
WindMIL Therapeutics and Stephenson Cancer Center announce collaboration to collect bone marrow from patients with renal and urothelial carcinomas ... Oct 14
Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung ... Sep 21
But risk of some cancers, including basal cell carcinoma, some types of breast cancer and ovarian cancer is increased, study shows ... Sep 04
Keytruda would be soon launched in Japan for the treatment of cancerous tumors... Aug 27
Option would extend dosing to four weeks in non-small cell lung and bladder cancer reducing medical visits by half ... Aug 20
Patients will be treated with intralesional injections of Nidlegy and it has already shown promising results.... Jun 26
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
